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Introduction {#sec1}
============

Horses are invaluable animals for companionship and sport. The equine industry creates an estimated economic impact of US\$300 billion worldwide, and novel means for addressing equine health issues are constantly required ([@bib22]). Musculoskeletal problems, including pathologies or injuries of muscle and cartilage, constitute a leading health threat among horses ([@bib20]). As an example, equine atypical myopathy has been increasingly reported over recent years ([@bib24]), and equine osteochondrosis is relatively frequent across different breeds ([@bib23]). Therefore, the quest for novel tools for muscle and cartilage repair is still compelling. In this regard, stem cells may support the needs of veterinary medicine ([@bib7]). In equine practice, mesenchymal stem cells (MSCs) are commonly used to treat tendinitis and osteoarthritis ([@bib17]). However, a comprehensive regenerative approach tailored to both muscle and cartilage is still missing, especially for large-scale applications. Importantly, considering the obvious difficulties of in vivo trials, in vitro models constitute a useful, first-line trial platform for addressing differentiation and heterogeneity of stem cells ([@bib9]). To this end, induced pluripotent stem cells (iPSCs) hold great potential, in light of their tremendous expansion capacity and wide differentiation potential ([@bib25]). Recently, iPSCs have been generated from equine fibroblasts ([@bib3]) and keratinocytes ([@bib18]); however, their differentiation potential toward myocytes or chondrocytes remains unknown. Furthermore, iPSCs tend to retain, at least partially, the intrinsic fate propensity of the cell source ([@bib16]). In mice, iPSCs derived from resident myogenic pericytes, i.e. mesoangioblasts (MABs), show biased myogenic differentiation in both teratoma and in vitro differentiation assays ([@bib12]). However, it is still unknown whether it is possible to discriminate the intrinsic equine iPSC propensity toward the myogenic and the chondrogenic lineages. To address this question, isogenic settings need to reduce the variability introduced by genetic background ([@bib11]). Relevantly for putative veterinary applications, the choice of the cell source should be confined to somatic compartments at facilitated reach, e.g. blood and superficial muscle biopsies. Equine peripheral blood has been recently used to isolate circulating progenitors, exhibiting MSC properties ([@bib21]) and differentiating in chondrocytes ([@bib4]). With regard to the muscle, it is still unknown whether equine MABs can be isolated with similar characteristics to murine, canine, or human MABs ([@bib14], [@bib15]), and to which extent equine MABs display myogenic propensity, once cultured in vitro and after reprogramming.

Thus, the objective of this study is to compare iPSCs obtained from equine MABs and peripheral blood MSCs in isogenic conditions to evaluate the intrinsic iPSC propensity for myogenic and chondrogenic lineages.

Results {#sec2}
=======

To obtain source cells for reprogramming in isogenic settings ([Figure 1](#fig1){ref-type="fig"}A), we isolated equine MABs in isogenic settings with MSC lines, which were already established from peripheral blood ([@bib21]), and demonstrated chondrogenic commitment ([@bib4]). We adapted the procedures that were previously reported for murine and human MABs ([@bib13]) to biopsies obtained from the splenius muscles of three syngeneic horses, and accordingly sorted the heterogeneous cell population for alkaline phosphatase (AP) (1.5% ± 0.6% \[mean ± SD; n = 3\]). AP activity was confirmed in the AP^+^ but not the AP^−^ fraction ([Figure 1](#fig1){ref-type="fig"}B). At early passage (\<3), AP^+^ cells proliferated with a doubling time of approximately 27 hr and stained positively for NG2, CD140a, CD140, and CD44, pericytic surface markers reported for murine and human MABs ([@bib13]) ([Figure 1](#fig1){ref-type="fig"}C). Furthermore, after 7 days in serum starvation, the AP^+^ cells robustly differentiated into multinucleated, MyHC^+^ myotubes (fusion index, 27.5% ± 7.01% \[mean ± SD; n = 3\]), unlike the isogenic MSC controls ([Figure 1](#fig1){ref-type="fig"}D). We thus identified the AP^+^ cells as bona fide equine MABs, which show robust myogenic propensity compared with the isogenic MSCs. To obtain iPSCs, we transduced equine isogenic MABs and MSCs with retroviral vectors carrying human reprogramming factors (*OCT4*, *SOX2*, *KLF4*, *cMYC*), then picked and expanded single-cell clones (n = 3/cell type) on a feeder layer. Reprogramming efficiency was approximately 0.0001% for both cell types. Colonies of both MAB- and MSC-iPSCs appeared round-shaped and with compact borders, and were positive for AP, OCT4, SOX2, NANOG, and LIN28 staining ([Figure 1](#fig1){ref-type="fig"}E). The expression of the pluripotency markers *OCT4*, *SOX2*, *NANOG*, and *LIN28* was confirmed with specifically cross-reacting primers, using human H9 cells as positive control. Moreover, expression of retroviral transgenes was not detected in both equine iPSC types ([Figure 1](#fig1){ref-type="fig"}F). Also, equine iPSCs showed a euploid, donor-matching karyotype (n = 62, XX; [Figure 1](#fig1){ref-type="fig"}G). Furthermore, after 20 days of spontaneous in vitro differentiation, both MAB- and MSC-iPSCs differentiated in ectodermal (TUJ1^+^), endodermal (αFP^+^), and mesodermal (αSMA^+^) derivative cells ([Figure 1](#fig1){ref-type="fig"}H). Thus, equine isogenic MAB- and MSC-iPSCs shared common markers of pluripotency. To gain insight into iPSC intrinsic propensity, we subcutaneously injected equine iPSCs in immunodeficient mice and analyzed the teratomas at 4--6 weeks after injection. Both iPSC types generated teratomas containing immature derivatives of ectoderm, endoderm, and mesoderm, confirming their pluripotency ([Figure 2](#fig2){ref-type="fig"}A). However, MAB-iPSC teratomas showed a significantly higher quantity of immature muscle patches in comparison with MSC-iPSCs ([Figure 2](#fig2){ref-type="fig"}B). Conversely, MSC-iPSC teratomas showed significantly larger chondrogenic patches ([Figure 2](#fig2){ref-type="fig"}C). To exclude the contribution of host cells to teratoma derivatives, we stained equine iPSC teratoma sections for lamin A/C, using murine iPSC- and human iPSC-derived teratomas as negative and positive controls, respectively. Both MAB- and MSC-iPSC-derived teratomas stained positively to lamin A/C ([Figures 2](#fig2){ref-type="fig"}D and 2E), indicating that the teratoma tissues derived from equine iPSCs. Intrigued by the propensities shown in the teratoma assays, we asked whether the source-related propensity was significantly skewing the iPSC fate in dedicated differentiation assays. We tested the myogenic differentiation of iPSCs and related source cells under conditions of bone morphogenetic protein (BMP)/transforming growth factor β (TGF-β) blockade and assayed for MyHC^+^ myocytes and myotubes. After 30 days, MABs and MAB-iPSCs showed higher differentiation rates compared with isogenic MSCs and MSC-iPSCs ([Figures 3](#fig3){ref-type="fig"}A and 3B). Moreover, equine *MYH2* expression levels were significantly higher in differentiated MABs and MAB-iPSCs ([Figure 3](#fig3){ref-type="fig"}C). We then tested the chondrogenic differentiation in compacted spheres ([@bib21]) and assayed for Alcian blue-positive structures. Only MSC- and MSC-iPSC-derived spheres showed consistent chondrogenic differentiation, assayed as larger chondrogenic patches and lower cell density when compared with undifferentiated spheres ([Figures 4](#fig4){ref-type="fig"}A and 4B). Accordingly, equine *COMP* expression levels were significantly induced only in differentiated MSC and MSC-iPSC spheres, and appeared non-detectable in MABs and MAB-iPSCs ([Figure 4](#fig4){ref-type="fig"}C). Furthermore, in light of the adipogenic potential of equine MSCs ([@bib21]), we tested the differentiation efficiency of equine iPSCs toward the adipogenic lineage. Intriguingly, albeit generally limited and variable, the differentiation efficiency into Oil Red^+^ adipocytes appeared higher in MSC-iPSCs than in MAB-iPSCs ([Figure 4](#fig4){ref-type="fig"}D), indicating a possible retention of MSC propensity toward other lineages as well. Thus, in both teratoma and in vitro assays, equine isogenic iPSCs showed intrinsic, discriminable propensities toward the lineages of source stem cells, e.g. myogenic in MAB-iPSCs and chondrogenic in MSC-iPSCs.

Discussion {#sec3}
==========

Inconsistencies among cell source isolation and reprogramming techniques can result in iPSCs that may appear similar, but have very different capacities to modulate or contribute to tissue regeneration ([@bib1], [@bib10]). In addition, several studies on the epigenetic variations in iPSCs have raised concerns that these dissimilarities may compromise the clinical applications of iPSCs ([@bib19]). Our data indicate that source-related intrinsic propensity is retained in iPSCs, and quantitatively primes their differentiation toward skeletal muscle and cartilage lineages. The iPSCs used in our study were obtained with human reprogramming factors, and appeared genuinely reprogrammed as equine endogenous genes were reactivated (*NANOG*, *LIN28*) and retroviral transgenes were silenced. Albeit far from comprehensive, the pluripotency characterization of our cells is consistent with that of other equine iPSC lines previously reported by independent groups ([@bib3], [@bib18]). However, a more translationally relevant insight is expected when non-integrative vectors carrying the equine ortholog factors will be available. Xeno-free conditions for reprogramming and expansion will be necessary also for properly addressing the durability of such propensity (our studies are limited to passage 8 after clone isolation). Such a strategy will indeed allow more refined studies, including epigenetic analyses. In this regard, our in vitro data support the notion that not all epigenetic signatures of parental stem cells are equally erased during reprogramming, thus altering the differentiation efficiency of iPSCs. The effects appeared relevant for myogenic and chondrogenic lineages. Our results showing enhanced differentiation with equine iPSCs seem consistent with the findings previously reported with murine MAB-iPSCs ([@bib12]) and human reprogrammed chondrocytes ([@bib2]). In this regard, an important issue to be considered is that we reprogrammed MABs and MSCs, and not differentiated cells, i.e. myocytes and chondrocytes. This was based on clinical and experimental reasons. From a translational perspective for iPSC applications, stem cells are likely superior to terminally differentiated progenies, due to greater expansion ability and higher susceptibility to reprogramming protocols ([@bib6]). Moreover, MABs and MSCs are currently under clinical trial scrutiny in human patients for the treatment of muscle (EudraCT\#2011-000176-33) and cartilage conditions (US-CT\#NCT01879046). Also, our attempts to reprogram the differentiated progenies of equine MABs and MSCs failed (data not shown), likely due to very low transduction efficiency and halted proliferation. Importantly, as shown by the results of parallel differentiation of parental cells and iPSCs, MAB- and MSC-iPSCs efficiently retained the myogenic and chondrogenic differentiation biases, respectively. However, it remains unknown whether MSCs from other body regions (e.g. bone marrow, adipose tissue) will exhibit different levels of chondrogenic bias and reprogramming potency. Furthermore, our results for the adipogenic lineage, although limited to the iPSC pools, suggest that other differentiation propensities might be retained too, albeit likely with different efficiencies. Dedicated studies are needed to address this point, as the purpose of our study was centered on muscle and cartilage. In conclusion, the observations reported here hint at further studies of in vivo/in vitro differentiation, possibly in combination with known genetic defects and tailored corrections, in order to better harness the potential of equine iPSCs for veterinary disease modeling and regenerative medicine.

Experimental Procedures {#sec4}
=======================

Cell Isolation and Expansion {#sec4.1}
----------------------------

All procedures involving live horses were performed under the specifications of the Ethical Approval Forms EC_2012_001 for blood withdrawal and EC_2014_003 for muscle tissue sampling (Ethics Committee, Global Stem Cell Technology). Equine MABs were isolated from three syngeneic female siblings of the French trotter breed aged between 5 and 7 years. Splenius muscle biopsies were taken in sterile conditions under local anesthesia, and equine MABs were isolated using previously reported procedures for murine and human MABs ([@bib13]). In brief, muscle biopsy pieces (approximately 2 × 2 × 2 mm) were cultured on collagen (Sigma-Aldrich)-coated dishes (NUNC) and MABs were isolated as AP^+^-sorted population from the outgrowths. Peripheral blood MSCs from the same horses were already isolated and characterized ([@bib21]). Equine MABs were then passaged and expanded on collagen-coated culture vessels (NUNC) in IMDM10% medium (IMDM supplemented with 10% FBS, 1% penicillin-streptomycin \[pen/strep\], 1% L-glutamine, 1% sodium pyruvate, 1% non-essential amino acids \[NEAA\], 1% insulin-transferrin-selenium supplement \[Thermo Fisher\], 0.2% 2-mercaptoethanol, and 5 ng/ml basic fibroblast growth factor \[bFGF; Peprotech\]) at 5% O~2~/5% CO~2~ and 37°C. Equine MSCs were passaged and expanded on tissue culture vessels (NUNC) in DMEM10% medium (DMEM supplemented with 10% FBS, 1% pen/strep, 1% L-glutamine, and 1% sodium pyruvate) at 5% O~2~/5% CO~2~ and 37°C. Equine cells were reprogrammed analogously to procedures described for murine iPSCs ([@bib12]). In brief, cells were transduced with retroviral particles carrying human *OCT4*, *SOX2*, *KLF4*, and *CMYC* cDNA sequences (pMX vectors, Addgene) and seeded at low confluence on a feeder layer of mitomycin-treated primary murine embryonic fibroblasts (iMEFs). Reprogramming efficiency was calculated as percentage of ESC-like colonies versus starting cell number prior to transduction. Equine iPSC colonies were picked at 4--5 weeks after transduction, clonally expanded, and characterized for pluripotency marker expression. Equine MAB- and MSC-iPSCs were cultured on a feeder layer of iMEFs in equine iPSC medium (DMEM-F12 with Nutrient mix and HEPES, supplemented with 20% KnockOut serum, 1% pen/strep, 1% NEAA, 0.2% 2-mercaptoethanol, and 5 ng/ml bFGF) at 5%O~2~/5%CO~2~ and 37°C.

Differentiation Assays {#sec4.2}
----------------------

The myogenic propensity of somatic MABs and MSCs was tested in serum starvation conditions, i.e. in DMEM2% medium (high-glucose DMEM supplemented with 2% horse serum \[Thermo Fisher\], 1% pen/strep, and 1% L-glutamine) for 7 days. Fusion index was calculated as the percentage of nuclei enclosed in myotubes per field. For myogenic differentiation, iMEF-deprived iPSCs were seeded at 4,000 cells/cm^2^ on gelatin (Millipore)-coated vessels, and kept in F12-20% medium (DMEM-F12 with Nutrient mix and HEPES, supplemented with 20% FBS, 1% pen/strep, 1% NEAA, and 0.2% 2-mercaptoethanol) for 20 days. Cells were then reseeded at 4,000 cells/cm^2^ on gelatin-coated vessels and kept in F12-20% medium, supplemented with 1% insulin-transferrin-selenium (ITS) supplement (Thermo Fisher), for 15 days. Terminal myogenic maturation was achieved in DMEM2% medium, supplemented with 1% ITS, 50 ng/ml recombinant human NOGGIN (BMP inhibitor; Thermo Fisher), and 1 μM SB431542 hydrate (TGF-β inhibitor; Sigma-Aldrich) for 15 days. All aforementioned differentiation assays were performed at 5% O~2~/5% CO~2~ and 37°C. To initiate chondrogenic differentiation, 3 × 10^5^ cells were resuspended in 5 ml of medium and centrifuged for 5 min at 150 × *g*. Subsequently, 0.5 ml of chondrogenic differentiation medium (basal differentiation medium \[Lonza\] supplemented with 10 ng/ml TGF-β~3~ \[Sigma\]) or expansion medium were added per pellet and refreshed twice a week. Four chondrospheres and four undifferentiated control spheres were established per cell type per horse, and evaluated after 10 days with Alcian blue staining and PCR. Adipogenic differentiation was induced with the Mesenchymal Adipogenesis Assay (Millipore) on plated embryoid bodies after cell sprouting (\>95% confluence). The manufacturer\'s instructions were followed for differentiation cocktails, timing, and staining.

Teratoma Assay {#sec4.3}
--------------

All procedures involving live mice were performed under the specifications of the Ethical Approval \#P150/2014 (Ethics Committee, KU Leuven). Immunodeficient 2-month-old *Rag2-null/Il2rg-null* mice were injected with a 100-μl suspension of 350,000 equine iPSCs in 1:2 diluted Matrigel (Thermo Fisher) subcutaneously in the nape region. Teratomas (n = 3/iPSC type) were retrieved between 4 and 6 weeks after injection, when visible and not yet ulcerated.

Immunofluorescence, Histological, and Colorimetric Staining {#sec4.4}
-----------------------------------------------------------

Immunofluorescence staining was performed following the commonly used steps of Triton-based (Sigma-Aldrich) permeabilization (avoided for MAB surface marker staining), background blocking with donkey serum (Sigma-Aldrich), overnight incubation with primary antibody at 4°C, 1 hr of incubation with 1:500 AlexaFluor-conjugated donkey secondary antibodies (Thermo Fisher), and final counterstain with Hoechst. Here follows the list of primary antibodies and relative dilutions: mouse anti-NG2 PE-conjugated (R&D Systems \#MAB6689), 1:100; mouse anti-CD140a and anti-CD140b APC-conjugated (Antibodies Online \#ABIN910520/ABIN457302), 1:50; mouse anti-CD44 APC-conjugated (eBioscience \#17-0441-81), 1:200; goat anti-OCT4 (Abcam \#ab19857), 1:500; goat anti-SOX2 (Santa Cruz \#sc-17320), 1:100; rabbit anti-Nanog (Abcam \#ab80892), 1:500; goat anti-Lin28 (Santa Cruz \#sc-54032), 1:100; mouse anti-MyHC (DSHB, \#MF20), 1:8; rabbit anti-TUJ1 (Millipore \#04-1049), 1:300; rabbit anti-αFP (Abcam \#ab87635), 1:500; mouse anti-αSMA (Sigma-Aldrich \#A2547), 1:300; mouse anti-lamin A/C (Millipore \#05-714), 1:100. Histological staining (H&E and Alcian blue, reagents from Roche-Ventana; Masson trichrome, reagents from Sigma-Aldrich) was performed on 5-μm-thick slices from paraffin-embedded tissue pieces following the manufacturer\'s instructions. AP staining was performed exposing 2% PFA-fixed cells to the BCT/NBT reagent (Sigma-Aldrich; resuspended in dH~2~O) for 1 hr. Quantitation of myogenic differentiation was performed on at least ten independent fields per cell type. Quantitation of teratoma derivatives and chondrogenic differentiation of the microspheres was performed on at least ten serial sections (approximately 100-μm interval between consecutive sections).

Molecular Assays {#sec4.5}
----------------

For pluripotency marker expression, 1:5 diluted cDNA was obtained from 1 μg of total RNA (SSIII cDNA production kit and RNA extraction kit from Thermo Fisher). RT-PCR was performed using Taq polymerase-associated reagents (Thermo Fisher) and conditions (95°C 30 s, 60°C 30 s, 72°C 60 s; 40× for endogenous, 25× for retroviral genes). Primers: *OCT4* Fw GAGGCTCTGCAGCTCAGTTT, Rev CTCCAGGTTGCCTCTCACTC; *SOX2* Fw AACCAGCGCATGGACAGTTA, Rev GACTTGACCACCGAACCCAT; *NANOG* Fw ATACCTCAGCCTCCAGCAGA, Rev AGCCCCGGGTAGTCTGTAGT; *LIN28* Fw TGTAAGTGGTTCAACGTGCG, Rev CAGCTTACTCTGGTGCACAA; *PGK* Fw CTGGGCAAGGATGTTTTGTT, Rev TATTTTGGCTGGCTCAGCTT; *retrov-OCT4* Fw CCCCAGGGCCCCATTTTGGTACC; *retrov-SOX2* Fw GGCACCCCTGGCATGGCTCTTGGCTC; *retrov-KLF4* Fw ACGATCGTGGCCCCGGAAAAGGACC; *retrov-cMYC* Fw CAACAACCGAAAATGCACCAGCCCCAG; *pMX Rev* (for all retrov-primers) TTATCGTCGACCACTGTGCTGCTG. *MYH2* qRT-PCR was performed by means of SybrGreen mix (Thermo Fisher) using the Viia7 384-plate reader (Thermo Fisher; final primer concentration, 100 nM; final volume, 10 μl; *PGK*, internal reference; thermal profile, 95°C 15 s, 60°C 60 s, 40×). Primers: *MYH2* Fw TGAGTCCCAGGTCAACAAGC, Rev TTCCATAGCGTGAAGGCATGA. For the *COMP* qRT-PCR assay, total RNA (totRNA) was isolated with the High Pure Isolation Kit (Roche Diagnostics). TotRNA integrity was evaluated using the Agilent 2100 Bioanalyzer (Agilent Technologies; RIN values, 8.8--10). TotRNA was reverse transcribed with the iScript cDNA Kit (Bio-Rad). qRT-PCR assay for *COMP* and reference genes *SDHA* and *ACTB* (selected with geNorm) was performed with FastStart essential DNA Green Master (Roche Diagnostics) on the LightCycler 480 (Roche) with following cycling conditions: 20 s at 95°C, 40 s at annealing temperature (*sdha*, 59°C; *actb*, *comp*, 60°C), 1 min at 72°C, 45×. *SDHA*, *ACTB* primers: see [@bib8]. *COMP* primers: Fw GACTACGCGGGCTTCATCTT, rev CTGCTCCATCTGCTTCCACA. Specificity was proved through melting curve analysis. Expression levels were analyzed and normalized using qBase+ (version 3.0). Assays were performed according to the MIQE guidelines ([@bib5]).

Statistical Analysis {#sec4.6}
--------------------

Power analysis was performed using Sample Size Calculator (power, 0.80; alpha, 0.05). Statistical tests were chosen based on data distribution. For teratoma derivatives, the Mann-Whitney U test was applied (p \< 0.05). For *MYH2* levels, the unpaired t test was applied (p \< 0.05). For myogenic efficiency, chondrogenic efficiency, *COMP* levels, and cell density, one-way ANOVA with Bonferroni multi-comparison was applied (p \< 0.05). All tests were performed by means of Prism v5.0 (GraphPad).
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![Generation of Equine MAB- and MSC-iPSCs in Isogenic Conditions\
(A) Schematic experimental plan.\
(B) AP activity staining on AP^+^ (positive signal) and AP^−^ (background signal) cell fractions from the skeletal muscle.\
(C) Immunofluorescence staining for pericytic markers and related isotypes of equine MABs (AP^+^ cells).\
(D) MyHC immunofluorescence staining of equine MABs and MSCs after serum starvation. Myogenic differentiation is apparent as multinucleated myotubes.\
(E) Panel of pluripotency characterization for equine iPSCs.\
(F) (Left) RT-PCR with specifically cross-reacting (equine-human) primers (eq-, negative equine control, parental cells; hu+, human positive control, H9 ESCs; rt-, negative control of reverse transcription). (Right) RT-PCR for expression of retroviral (retrov-) reprogramming factors (ct+, positive control, fibroblasts freshly transduced with the reprogramming retroviruses).\
(G) Euploid karyograms of equine iPSCs at passage 3.\
(H) Immunofluorescence analysis for markers of ectodermal (TUJ1^+^), endodermal (αFP^+^), and mesodermal (αSMA^+^) derivative cells after spontaneous iPSC differentiation. All results shown were obtained from cell clones from all three donors (n = 3 independent experiments/cell type).\
Scale bars, 100 μm.](gr1){#fig1}

![Equine iPSC Intrinsic Propensities to Muscle and Cartilage Derivatives in Teratomas\
(A) Representative pictures of derivatives (arrowheads) of ectoderm (upper, ectodermal cysts; lower, neural tube), endoderm (unstructured, gland-like acinar tissues), and mesoderm (upper, adipose tissue; lower, immature bone structures).\
(B) Quantitation of striated muscle patches (white arrows) by means of Masson trichrome staining (^∗^p \< 0.05, Mann-Whitney U test, n = 3 independent experiments per cell type).\
(C) Quantitation of chondrogenic patches (black arrows) by means of Alcian blue staining (^∗^p \< 0.05, Mann-Whitney U test, n = 3 independent experiments per cell type).\
(D) Immunofluorescence staining for lamin A/C on equine iPSC teratomas (n = 4/cell type; ct-, negative control, murine iPSC teratoma; ct+, positive control, human iPSC teratoma).\
(E) Staining for lamin A/C and markers of ectodermal (TUJ1), endodermal (αFP), and mesodermal (SARCαACT) derivatives in equine MAB-iPSC-derived teratomas (n = 4 technical replicates per cell type). Magnifications of highlighted fields are shown to the right of original panels to evidence co-localization of lamin A/C (nuclear membrane) and the cytoplasmic markers. Comparable results were obtained with MSC-iPSCs (data not shown).\
Histograms represent average values; error bars indicate SD. Scale bars, 100 μm.](gr2){#fig2}

![Assessment of Equine iPSC Myogenic Differentiation\
(A) Immunofluorescence staining for MyHC of parental cells and iPSCs under BMP/TGF-β blockade.\
(B) Quantitation of differentiation efficiency as fraction of cells participating to nascent MyHC^+^ myotubes (fusion index; ^∗^p \< 0.05, one-way ANOVA with Bonferroni comparison, n = 3 independent experiments per cell type).\
(C) qRT-PCR with equine-specific *MYH2* primers; data are depicted as fold change versus MABs or MAB-iPSCs (AU, arbitrary units; ^∗^p \< 0.05, unpaired t test, n = 3 independent experiments per cell type). Both analyses revealed higher myogenic propensity in MAB-iPSCs than in MSC-iPSCs (n = 3 independent experiments per cell type).\
Histograms represent average values; error bars indicate SD. Scale bars, 100 μm.](gr3){#fig3}

![Assessment of Equine iPSC Chondrogenic Differentiation\
(A) Alcian blue staining for undifferentiated and chondrogenic microspheres. Indicated percentages refer to the Alcian blue-positive areas (arrows) across the depicted spheres.\
(B) Quantitation of cell density and differentiation efficiency in parental cells and iPSCs, comparing undifferentiated (undiff) and differentiated (chondro) spheres (^∗^p \< 0.05, one-way ANOVA with Bonferroni comparison; ns, not significant).\
(C) qRT-PCR with equine-specific *COMP* primers; data are depicted as fold change versus undiff (AU, arbitrary units; nd, not detectable; ^∗^p \< 0.05, one-way ANOVA with Bonferroni comparison; n = 3 independent experiments \[3 technical replicates per experiment/cell type\]).\
(D) Oil Red staining on MAB- and MSC-iPSCs after adipogenic differentiation (red lipid vacuoles denote adipocyte-like cells). Differentiation rate is quantitated as percentage of adipocytes per field (^∗^p \< 0.05, Mann-Whitney U test, n = 3/cell type, n = 3 independent experiments per cell type).\
Histograms represent average values; error bars indicate SD. Scale bars, 100 μm.](gr4){#fig4}

[^1]: Co-senior author
